Compounding Pharmacists Unhappy With New FDA Guidance Documents: Rules Severely Limit Distribution

類似資料

• FDA to Collect Patient Experience Data: Upcoming Guidance Documents Will Spell Out What and How to Submit
  著者:: Barlas, Stephen
  出版事項: (2018)
• Two Draft FDA Guidance Documents Stir Controversy: Hospital and 503B Pharmacy Repackaging and Compounding Are at Issue
  著者:: Barlas, Stephen
  出版事項: (2015)
• FDA Draft Guidances Compound the Compounding Uncertainty: A New List of 503B Outsourcing Facilities Offers No Guarantee of Anything
  著者:: Barlas, Stephen
  出版事項: (2014)
• Pharmacists Welcome FDA’s Opioids REMS: How Directly Will They Be Affected?
  著者:: Barlas, Stephen
  出版事項: (2012)
• Pharmacists, Deluged With Requirements, Pressure FDA to Standardize REMS Programs
  著者:: Barlas, Stephen
  出版事項: (2014)